Piccolo R, et al. - Since new-generation drug-eluting stents (DES) were mostly assessed in head-to-head non-inferiority trials against early-generation DES and usually displayed comparable effectiveness and better safety, researchers compared results among patients undergoing percutaneous coronary intervention after implantation of new-generation DES vs bare-metal stents (BMS). Due to a reduced risk of myocardial infarction and a slight but non-significant benefit in cardiac mortality, the risk of the primary outcome (the composite of cardiac death or myocardial infarction) was reduced in DES recipients vs BMS recipients. In the first year after implantation, the performance of the new generation DES means that BMS should no longer be considered the safety gold standard.